← All trials
NCT05096403
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- May 31, 2024
- Completion date
- Jun 30, 2024
- First posted
- Oct 27, 2021
- Last posted
- Oct 27, 2021
- Enrollment
- 57
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Swedish Orphan BiovitrumLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.